## David Sidransky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11406539/publications.pdf

Version: 2024-02-01

427 papers 45,049 citations

103 h-index 195 g-index

430 all docs 430 docs citations

430 times ranked

39634 citing authors

#	Article	IF	CITATIONS
1	Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. Journal of the National Cancer Institute, 2000, 92, 709-720.	3.0	2,586
2	5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1995, 1, 686-692.	15.2	1,812
3	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in $\langle i \rangle$ NOTCH1 $\langle i \rangle$ . Science, 2011, 333, 1154-1157.	6.0	1,568
4	Head and Neck Cancer. New England Journal of Medicine, 2001, 345, 1890-1900.	13.9	1,176
5	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6373-6379.	1.8	893
6	BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2003, 95, 625-627.	3.0	849
7	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
8	Facile Detection of Mitochondrial DNA Mutations in Tumors and Bodily Fluids. Science, 2000, 287, 2017-2019.	6.0	767
9	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. Journal of the National Cancer Institute, 2003, 95, 484-486.	3.0	762
10	Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 1995, 332, 429-435.	13.9	690
11	<i>TP53</i> Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2007, 357, 2552-2561.	13.9	680
12	Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 1992, 355, 846-847.	13.7	628
13	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics, 1995, 11, 210-212.	9.4	593
14	Emerging molecular markers of cancer. Nature Reviews Cancer, 2002, 2, 210-219.	12.8	590
15	Association between Cigarette Smoking and Mutation of the p53 Gene in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 1995, 332, 712-717.	13.9	578
16	Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Medicine, 1996, 2, 1035-1037.	15.2	570
17	Clonal Origin of Bladder Cancer. New England Journal of Medicine, 1992, 326, 737-740.	13.9	496
18	Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Research, 2002, 62, 3659-62.	0.4	462

#	Article	IF	Citations
19	p16(MTS-1/CDKN2/INK4a) in Cancer Progression. Experimental Cell Research, 2001, 264, 42-55.	1.2	415
20	Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001, 92, 1525-1530.	2.0	381
21	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	5 <b>.</b> 8	372
22	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Molecular Cancer Therapeutics, 2011, 10, 1311-1316.	1.9	354
23	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	1.6	333
24	Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell, 2002, 2, 485-495.	7.7	315
25	DNA methylation markers in colorectal cancer. Cancer and Metastasis Reviews, 2010, 29, 181-206.	2.7	259
26	Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Medicine, 1997, 3, 621-624.	15.2	248
27	Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Research, 2002, 62, 371-5.	0.4	240
28	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2867-2872.	1.8	239
29	MicroRNA alterations in head and neck squamous cell carcinoma. International Journal of Cancer, 2008, 123, 2791-2797.	2.3	239
30	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF $\hat{l}^2$ enhance the efficacy of cancer immunotherapy. Nature Communications, 2018, 9, 741.	5.8	238
31	Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. Journal of the National Cancer Institute, 2006, 98, 996-1004.	3.0	237
32	16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget, 2016, 7, 51320-51334.	0.8	237
33	A new human p53 homologue. Nature Medicine, 1998, 4, 747-748.	15.2	235
34	A Quantitative Promoter Methylation Profile of Prostate Cancer. Clinical Cancer Research, 2004, 10, 8472-8478.	3.2	234
35	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 2015, 35, S5-S24.	4.3	231
36	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. Clinical Cancer Research, 2011, 17, 7248-7264.	3.2	230

#	Article	IF	CITATIONS
37	Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects. Journal of Clinical Oncology, 2005, 23, 6569-6575.	0.8	227
38	Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 2001, 20, 5195-5198.	2.6	220
39	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
40	Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4262-4269.	0.8	219
41	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. Genome Research, 2004, 14, 812-819.	2.4	218
42	Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer. Cancer Research, 2004, 64, 5511-5517.	0.4	218
43	Head and Neck Cancer in CNonsmokers: A Distinct Clinical and Molecular Entity. Laryngoscope, 1999, 109, 1544-1551.	1.1	216
44	Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules. Clinical Cancer Research, 2004, 10, 2761-2765.	3.2	213
45	Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive <i>p53</i> Gene Mutations in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2008, 14, 366-369.	3.2	213
46	Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Research, 2005, 7, R609-16.	2.2	207
47	î"Np63 induces β-catenin nuclear accumulation and signaling. Cancer Cell, 2002, 1, 369-379.	7.7	197
48	Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology, 2002, 60, 1131-1135.	0.5	196
49	p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study. Journal of the National Cancer Institute, 2003, 95, 961-970.	3.0	196
50	Uncommon Mutation, but Common Amplifications, of the PIK3 CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4688-4693.	1.8	189
51	DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Research, 2003, 63, 2351-7.	0.4	184
52	Activation of the <i>NOTCH</i> Pathway in Head and Neck Cancer. Cancer Research, 2014, 74, 1091-1104.	0.4	181
53	Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 1998, 16, 3215-3218.	2.6	175
54	Involvement of aquaporins in colorectal carcinogenesis. Oncogene, 2003, 22, 6699-6703.	2.6	175

#	Article	IF	Citations
55	Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7540-7545.	3.3	175
56	Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics, 2010, 5, 539-546.	1.3	172
57	Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes and Cancer, 1997, 19, 90-96.	1.5	169
58	CLINICAL IMPLICATIONS OF THE p53 GENE. Annual Review of Medicine, 1996, 47, 285-301.	5.0	168
59	Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1838-1843.	3.3	164
60	Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. International Journal of Molecular Medicine, 2014, 34, 941-946.	1.8	164
61	Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer. Clinical Cancer Research, 2004, 10, 2284-2288.	3.2	163
62	Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 97-107.	3.2	163
63	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology, 2004, 17, 1359-1363.	2.9	161
64	PGP9.5 As a Candidate Tumor Marker for Non-Small-Cell Lung Cancer. American Journal of Pathology, 1999, 155, 711-715.	1.9	160
65	Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer, 2005, 116, 920-924.	2.3	160
66	Mitochondrial Subversion in Cancer. Cancer Prevention Research, 2011, 4, 638-654.	0.7	160
67	Patientâ€derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	2.0	154
68	Aquaporin 1 Is Overexpressed in Lung Cancer and Stimulates NIH-3T3 Cell Proliferation and Anchorage-Independent Growth. American Journal of Pathology, 2006, 168, 1345-1353.	1.9	150
69	Increased Mitochondrial DNA Content in Saliva Associated with Head and Neck Cancer. Clinical Cancer Research, 2005, 11, 2486-2491.	3.2	148
70	Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. International Journal of Cancer, 2010, 126, 2991-2996.	2.3	146
71	Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.4	142
72	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 2014, 20, 2476-2484.	3.2	140

#	Article	IF	CITATIONS
73	Differential Recognition of Response Elements Determines Target Gene Specificity forp53 and p63. Molecular and Cellular Biology, 2005, 25, 6077-6089.	1.1	136
74	Quantitative Gstp1 Methylation Clearly Distinguishes Benign Prostatic Tissue And Limited Prostate Adenocarcinoma. Journal of Urology, 2003, 169, 1138-1142.	0.2	135
75	Role of Human Aquaporin 5 In Colorectal Carcinogenesis. American Journal of Pathology, 2008, 173, 518-525.	1.9	133
76	Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene, 2001, 20, 3528-3532.	2.6	132
77	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. Cancer Research, 2008, 68, 2661-2670.	0.4	131
78	Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 8321-8325.	3.2	129
79	Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nature Communications, 2015, 6, 8258.	5.8	129
80	Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites: Fig. 1 Clinical Cancer Research, 2004, 10, 3444-3447.	3.2	128
81	Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing. Cancer Research, 2004, 64, 5982-5987.	0.4	127
82	An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA. Clinical Cancer Research, 2011, 17, 4494-4503.	3.2	126
83	In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. Nature Communications, 2016, 7, 13427.	5.8	126
84	Expression of Aquaporin 5 (AQP5) Promotes Tumor Invasion in Human Non Small Cell Lung Cancer. PLoS ONE, 2008, 3, e2162.	1.1	124
85	The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors. Cancer Research, 2014, 74, 3995-4005.	0.4	123
86	High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients. Clinical Cancer Research, 2007, 13, 6122-6129.	3.2	122
87	Key tumor suppressor genes inactivated by "greater promoter―methylation and somatic mutations in head and neck cancer. Epigenetics, 2014, 9, 1031-1046.	1.3	122
88	Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Research, 2003, 63, 2216-22.	0.4	122
89	Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. American Journal of Surgery, 1994, 168, 429-432.	0.9	121
90	Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clinical Cancer Research, 2003, 9, 1370-5.	3.2	120

#	Article	IF	CITATIONS
91	Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clinical Cancer Research, 2002, 8, 481-7.	3.2	119
92	Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors., 1998, 23, 239-243.		117
93	Lack of BRAF Mutation in Primary Uveal Melanoma. , 2003, 44, 2876.		117
94	Quantitative RARÎ <sup>2</sup> 2 Hypermethylation. Clinical Cancer Research, 2004, 10, 4010-4014.	3.2	117
95	Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer. Cancer Research, 2008, 68, 700-706.	0.4	117
96	Intraoperative Molecular Margin Analysis in Head and Neck Cancer. JAMA Otolaryngology, 2004, 130, 39.	1.5	116
97	A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA. Clinical Cancer Research, 2017, 23, 7141-7152.	3.2	116
98	Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochemical and Biophysical Research Communications, 2008, 370, 38-43.	1.0	115
99	Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene, 1999, 18, 5843-5849.	2.6	113
100	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies. Journal of the National Cancer Institute, 2003, 95, 1634-1637.	3.0	110
101	PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma. Cancer Research, 2005, 65, 4963-4968.	0.4	110
102	Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers. PLoS ONE, 2012, 7, e44951.	1.1	110
103	Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers. Cancer Research, 2010, 70, 2870-2879.	0.4	107
104	Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research, 2003, 63, 2316-21.	0.4	107
105	Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. International Journal of Cancer, 2000, 86, 684-689.	2.3	106
106	Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. International Journal of Cancer, 2005, 117, 605-610.	2.3	106
107	Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1. Oncogene, 2002, 21, 3003-3010.	2.6	105
108	Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR. Clinical Cancer Research, 2010, 16, 3463-3472.	3.2	105

#	Article	IF	Citations
109	Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clinical Cancer Research, 2002, 8, 1203-9.	3.2	105
110	An Overview on the Isolation and Analysis of Circulating Tumor DNA in Plasma and Serum. Annals of the New York Academy of Sciences, 2000, 906, 8-12.	1.8	104
111	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes and Cancer, 2004, 41, 170-177.	1.5	103
112	A transcriptional progression model for head and neck cancer. Clinical Cancer Research, 2003, 9, 3058-64.	3.2	103
113	LOXL1 and LOXL4 Are Epigenetically Silenced and Can Inhibit Ras/Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder Cancer. Cancer Research, 2007, 67, 4123-4129.	0.4	102
114	Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase. Cancer Investigation, 2005, 23, 643-650.	0.6	101
115	An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer. Cancer Research, 2011, 71, 3812-3821.	0.4	101
116	RACK1 and Stratifin Target & Delta; Np63& Delta; Np63& Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage. Cell Cycle, 2004, 3, 1285-1295.	1.3	97
117	Assessment of gene promoter hypermethylation for detection of cervical neoplasia. International Journal of Cancer, 2006, 119, 1908-1914.	2.3	97
118	N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer. Cancer Research, 2006, 66, 3409-3418.	0.4	97
119	Proteomic analysis of cancer-cell mitochondria. Nature Reviews Cancer, 2003, 3, 789-795.	12.8	95
120	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4712-4718.	1.8	95
121	RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Human Molecular Genetics, 1994, 3, 1895-1897.	1.4	94
122	Molecular genetics of head and neck cancer. Current Opinion in Oncology, 1995, 7, 229-233.	1.1	94
123	ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin. Cell Cycle, 2005, 4, 1313-1315.	1.3	94
124	OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation. PLoS ONE, 2008, 3, e2990.	1,1	92
125	DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Research, 2005, 65, 758-66.	0.4	91
126	Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Human Pathology, 1999, 30, 1221-1225.	1,1	90

#	Article	IF	CITATIONS
127	Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clinical Cancer Research, 2002, 8, 2260-5.	3.2	89
128	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	2.3	88
129	Mitochondrial DNA Content Increase in Response to Cigarette Smoking. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 19-24.	1.1	87
130	Increased plasma DNA integrity index in head and neck cancer patients. International Journal of Cancer, 2006, 119, 2673-2676.	2.3	86
131	p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncology, 2011, 47, 8-15.	0.8	86
132	î"Np63α Overexpression Induces Downregulation of Sirt1 and an Accelerated Aging Phenotype in the Mouse. Cell Cycle, 2006, 5, 2005-2011.	1.3	85
133	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Molecular Cancer Research, 2006, 4, 1-8.	1.5	85
134	Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance. Clinical Cancer Research, 2011, 17, 4782-4789.	3.2	84
135	Chromosome 9p21 Loss and p16 Inactivation in Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma. Journal of Surgical Research, 1999, 84, 88-93.	0.8	83
136	Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma. Clinical Cancer Research, 2004, 10, 5518-5522.	3.2	82
137	Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Letters, 2008, 264, 54-62.	3.2	82
138	Cancer epigenetics: above and beyond. Toxicology Mechanisms and Methods, 2011, 21, 275-288.	1.3	82
139	Promoter DNA Methylation of Oncostatin M receptor- $\hat{l}^2$ as a Novel Diagnostic and Therapeutic Marker in Colon Cancer. PLoS ONE, 2009, 4, e6555.	1.1	81
140	p63α Mutations Lead to Aberrant Splicing of Keratinocyte Growth Factor Receptor in the Hay-Wells Syndrome. Journal of Biological Chemistry, 2003, 278, 23906-23914.	1.6	79
141	CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nature Medicine, 2004, 10, 374-381.	15.2	79
142	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. Journal of Clinical Oncology, 2012, 30, e45-e48.	0.8	79
143	High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i> , <i>Lactobacillus gasseri/johnsonii</i> , and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget, 2017, 8, 110931-110948.	0.8	79
144	Notch1 Mutations Are Drivers of Oral Tumorigenesis. Cancer Prevention Research, 2015, 8, 277-286.	0.7	78

#	Article	IF	CITATIONS
145	Mitochondrial DNA as a Cancer Biomarker. Journal of Molecular Diagnostics, 2005, 7, 258-267.	1.2	77
146	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. Cancer Research, 2018, 78, 168-181.	0.4	77
147	Aquaporin expression in human lymphocytes and dendritic cells. American Journal of Hematology, 2004, 75, 128-133.	2.0	76
148	Oxidized guanine lesions and hOgg1 activity in lung cancer. Oncogene, 2005, 24, 4496-4508.	2.6	76
149	Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney. Genes Chromosomes and Cancer, 1995, 12, 76-80.	1.5	75
150	T1799ABRAFMutations in Conjunctival Melanocytic Lesions. , 2005, 46, 3027.		75
151	KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. International Journal of Cancer, 2010, 127, 2351-2359.	2.3	75
152	Epigenetic inactivation of RASSF1A in head and neck cancer. Clinical Cancer Research, 2003, 9, 3635-40.	3.2	75
153	Mitochondrial DNA mutations in respiratory complex†in neverâ€smoker lung cancer patients contribute to lung cancer progression and associated with <i>EGFR</i> gene mutation. Journal of Cellular Physiology, 2012, 227, 2451-2460.	2.0	74
154	Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers. Electrophoresis, 1997, 18, 1742-1749.	1.3	73
155	Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2694-2700.	1.1	73
156	The effect of aquaporin 5 overexpression on the Ras signaling pathway. Biochemical and Biophysical Research Communications, 2008, 367, 291-298.	1.0	72
157	Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2786-2794.	1.1	72
158	Molecular Biology and the Early Detection of Carcinoma of the Bladder – The Case of Hubert H. Humphrey. New England Journal of Medicine, 1994, 330, 1276-1278.	13.9	70
159	Is human patched the gatekeeper of common skin cancers?. Nature Genetics, 1996, 14, 7-8.	9.4	69
160	Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML). PLoS ONE, 2008, 3, e2594.	1.1	69
161	Serum Protein MALDI Profiling to Distinguish Upper Aerodigestive Tract Cancer Patients From Control Subjects. Journal of the National Cancer Institute, 2003, 95, 1711-1717.	3.0	68
162	Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2984-2991.	1.1	68

#	Article	IF	CITATIONS
163	Integrated, Genome-Wide Screening for Hypomethylated Oncogenes in Salivary Gland Adenoid Cystic Carcinoma. Clinical Cancer Research, 2011, 17, 4320-4330.	3.2	68
164	A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochemical and Biophysical Research Communications, 2007, 354, 913-918.	1.0	67
165	Molecular techniques and genetic alterations in head and neck cancer. Oral Oncology, 2009, 45, 335-339.	0.8	67
166	<i>Endothelin Receptor Type B</i> Gene Promoter Hypermethylation in Salivary Rinses Is Independently Associated with Risk of Oral Cavity Cancer and Premalignancy. Cancer Prevention Research, 2010, 3, 1093-1103.	0.7	67
167	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer, 2010, 116, 5517-5526.	2.0	66
168	p53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways. Cancer Research, 2010, 70, 2274-2284.	0.4	66
169	Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy. Molecular Cancer Therapeutics, 2012, 11, 2429-2439.	1.9	66
170	MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1274-1278.	1.1	65
171	An Oligonucleotide Microarray for High-Throughput Sequencing of the Mitochondrial Genome. Journal of Molecular Diagnostics, 2006, 8, 476-482.	1.2	65
172	Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle, 2008, 7, 1613-1622.	1.3	65
173	Molecular detection approaches for smoking associated tumors. Oncogene, 2002, 21, 7289-7297.	2.6	64
174	Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Modern Pathology, 2005, 18, 898-902.	2.9	64
175	PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Research, 2006, 66, 3921-3927.	0.4	64
176	Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer. Clinical Cancer Research, 2009, 15, 1184-1191.	3.2	64
177	SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical Cancer Research, 2017, 23, 5162-5175.	3.2	64
178	Deleted in Colorectal Cancer Is a Putative Conditional Tumor-Suppressor Gene Inactivated by Promoter Hypermethylation in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2006, 66, 9401-9407.	0.4	63
179	Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. Cancer Research, 2006, 66, 9829-9836.	0.4	62
180	A tumor-suppressive role for trypsin in human cancer progression. Cancer Research, 2003, 63, 6575-8.	0.4	62

#	Article	IF	Citations
181	Mutation analysis of hBUB1 in aneuploid HNSCC and lung cancer cell lines. Cancer Letters, 1999, 139, 183-187.	3.2	61
182	p53 overexpression and K- ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2000, 7, 426-431.	2.0	61
183	Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: A New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model. Cancer Research, 2008, 68, 9033-9040.	0.4	61
184	Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance. PLoS ONE, 2011, 6, e20806.	1.1	61
185	The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clinical Cancer Research, 2003, 9, 2981-4.	3.2	61
186	Absence of V599EBRAF mutations in desmoplastic melanomas. Cancer, 2005, 103, 788-792.	2.0	60
187	Frequent 14-3-3 Ïf Promoter Methylation in Benign and Malignant Prostate Lesions. DNA and Cell Biology, 2005, 24, 264-269.	0.9	60
188	Quantitative hypermethylation of NMDAR2B in human gastric cancer. International Journal of Cancer, 2007, 121, 1994-2000.	2.3	60
189	Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecologic Oncology, 2007, 105, 662-666.	0.6	60
190	Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 98-104.	1.8	59
191	A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. International Journal of Cancer, 2011, 128, 1393-1403.	2.3	59
192	Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients., 1997, 74, 625-629.		58
193	Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Human Genome Variation, 2015, 2, 15009.	0.4	58
194	Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer, 2008, 8, 285.	1.1	57
195	Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 2019, 96, 77-88.	0.8	57
196	Molecular assessment of lymph nodes in patients with resected stage I non–small cell lung cancer: Preliminary results of a prospective study. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 466-474.	0.4	56
197	Mitochondrial DNA Mutation in Normal Margins and Tumors of Recurrent Head and Neck Squamous Cell Carcinoma Patients. Cancer Prevention Research, 2010, 3, 1205-1211.	0.7	56
198	OGDHL Is a Modifier of AKT-Dependent Signaling and NF-κB Function. PLoS ONE, 2012, 7, e48770.	1.1	56

#	Article	IF	CITATIONS
199	Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. International Journal of Cancer, 2001, 91, 200-204.	2.3	55
200	Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Molecular Cancer, 2006, 5, 73.	7.9	55
201	The role of PGP9.5 as a tumor suppressor gene in human cancer. International Journal of Cancer, 2008, 123, 753-759.	2.3	55
202	Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle, 2012, 11, 1656-1663.	1.3	55
203	Epigenetic Silencing of HOPX Promotes Cancer Progression in Colorectal Cancer. Neoplasia, 2012, 14, 559-IN6.	2.3	55
204	Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin. European Urology, 2000, 37, 350-357.	0.9	54
205	Altered Sumoylation of p63α Contributes to the Split-Hand/Foot Malformation Phenotype. Cell Cycle, 2004, 3, 1587-1596.	1.3	54
206	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine, 2006, 84, 911-918.	1.7	54
207	Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget, 2016, 7, 66239-66254.	0.8	54
208	Targeting of mutant hogg1in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress. BMC Cancer, 2006, 6, 235.	1.1	53
209	Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium. Biochemical and Biophysical Research Communications, 2008, 366, 321-327.	1.0	53
210	Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene, 2003, 22, 6954-6958.	2.6	52
211	Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2308-2316.	1.1	52
212	Colon cancer genetics. Cancer, 1992, 70, 1300-1312.	2.0	51
213	Decreased Mitochondrial DNA Content in Posttreatment Salivary Rinses from Head and Neck Cancer Patients. Clinical Cancer Research, 2006, 12, 1564-1569.	3.2	51
214	î"Np63α Confers Tumor Cell Resistance to Cisplatin through the AKT1 Transcriptional Regulation. Cancer Research, 2011, 71, 1167-1176.	0.4	51
215	Correlation between BRAF mutation and promoter methylation of TIMP3, RAR $\hat{I}^2$ 2 and RASSF1A in thyroid cancer. Epigenetics, 2012, 7, 710-719.	1.3	51
216	KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1611-1624.	1.9	51

#	Article	IF	CITATIONS
217	Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use. Cancer Prevention Research, 2015, 8, 208-221.	0.7	51
218	The <i>KRAS</i> -Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. JAMA Oncology, 2017, 3, 483.	3.4	51
219	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 376-382.	0.8	50
220	Integrated Analysis of Whole-Genome ChIP-Seq and RNA-Seq Data of Primary Head and Neck Tumor Samples Associates HPV Integration Sites with Open Chromatin Marks. Cancer Research, 2017, 77, 6538-6550.	0.4	50
221	Loss of Heterozygosity Assay for Molecular Detection of Cancer Using Energy-transfer Primers and Capillary Array Electrophoresis. Genome Research, 2000, 10, 1211-1218.	2.4	49
222	Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8715-8720.	3.3	49
223	Detection of LOH and Mitochondrial DNA Alterations in Ductal Lavage and Nipple Aspirate Fluids from High-risk Patients. Breast Cancer Research and Treatment, 2004, 84, 99-105.	1.1	49
224	QUANTITATIVE GSTP1 METHYLATION LEVELS CORRELATE WITH GLEASON GRADE AND TUMOR VOLUME IN PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2004, 171, 2195-2198.	0.2	48
225	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. Journal of Urology, 2008, 179, 743-747.	0.2	48
226	ATM kinase is a master switch for the Δ Np63α phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle, 2008, 7, 2846-2855.	1.3	48
227	GSTP1Promoter Methylation is Associated with Recurrence in Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 1542-1548.	0.2	48
228	MOLECULAR GENETICS AND BIOCHEMICAL MECHANISMS IN BLADDER CANCER. Urologic Clinics of North America, 1992, 19, 629-639.	0.8	48
229	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Research and Treatment, 2008, 109, 27-34.	1.1	47
230	Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Modern Pathology, 2008, 21, 979-991.	2.9	47
231	Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study. Molecular Cancer Research, 2004, 2, 289-295.	1.5	47
232	Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma: The Effect of Pre-analytical Factors. Annals of the American Thoracic Society, 2017, 14, 1169-1176.	1.5	45
233	Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. Oncotarget, 2016, 7, 61229-61245.	0.8	45
234	Molecular staging of head and neck squamous carcinoma. Cancer and Metastasis Reviews, 1996, 15, 3-10.	2.7	44

#	Article	IF	CITATIONS
235	Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head and Neck, 2004, 26, 870-877.	0.9	44
236	The effect of p53â€RNAi and p53 knockout on human 8â€oxoguanine DNA glycosylase (hOgg1) activity. FASEB Journal, 2006, 20, 112-114.	0.2	44
237	HOP/OB1/NECC1 Promoter DNA is Frequently Hypermethylated and Involved in Tumorigenic Ability in Esophageal Squamous Cell Carcinoma. Molecular Cancer Research, 2008, 6, 31-41.	1.5	44
238	BORIS Binding to the Promoters of Cancer Testis Antigens, <i>MAGEA2</i> , <i>MAGEA4</i> , ls Associated with Their Transcriptional Activation in Lung Cancer. Clinical Cancer Research, 2011, 17, 4267-4276.	3.2	44
239	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research, 2015, 75, 1287-1297.	0.4	44
240	High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Research, 2003, 63, 5723-6.	0.4	44
241	Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. International Journal of Cancer, 2002, 102, 615-617.	2.3	43
242	LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer. Cancer Research, 2006, 66, 7870-7879.	0.4	43
243	Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncology Reports, 2014, 32, 505-512.	1.2	43
244	Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prevention Research, 2015, 8, 287-295.	0.7	43
245	Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma. Cell Cycle, 2016, 15, 1643-1652.	1.3	43
246	Common pathway signature in lung and liver fibrosis. Cell Cycle, 2016, 15, 1667-1673.	1.3	43
247	Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. International Journal of Cancer, 2005, 113, 1022-1025.	2.3	41
248	Regulation of p53 Family Member Isoform ΔNp63α by the Nuclear Factor-κB Targeting Kinase IκB Kinase β. Cancer Research, 2010, 70, 1419-1429.	0.4	41
249	Characterization of the Methylation Patterns in Human Papillomavirus Type 16 Viral DNA in Head and Neck Cancers. Cancer Prevention Research, 2011, 4, 207-217.	0.7	41
250	Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients. Journal of Proteome Research, 2015, 14, 1900-1910.	1.8	41
251	The V599E BRAF mutation is uncommon in biliary tract cancers. Modern Pathology, 2004, 17, 1386-1391.	2.9	40
252	DCC promoter hypermethylation in esophageal squamous cell carcinoma. International Journal of Cancer, 2008, 122, 2498-2502.	2.3	40

#	Article	IF	CITATIONS
253	Neurofilament Heavy Polypeptide Regulates the Akt-β-Catenin Pathway in Human Esophageal Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e9003.	1.1	40
254	NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications, 2017, 8, 1772.	5.8	40
255	Cellular transformation by cigarette smoke extract involves alteration of glycolysis and mitochondrial function in esophageal epithelial cells. International Journal of Cancer, 2010, 127, 269-281.	2.3	39
256	Cigarette smoke induces promoter methylation of singleâ€stranded DNAâ€binding protein 2 in human esophageal squamous cell carcinoma. International Journal of Cancer, 2011, 128, 2261-2273.	2.3	39
257	Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate, 2008, 68, 418-426.	1.2	38
258	The Ras Effector RASSF2 Controls the PAR-4 Tumor Suppressor. Molecular and Cellular Biology, 2010, 30, 2608-2620.	1.1	38
259	Chronic Cigarette Smoke Mediated Global Changes in Lung Mucoepidermoid Cells: A Phosphoproteomic Analysis. OMICS A Journal of Integrative Biology, 2017, 21, 474-487.	1.0	38
260	Molecular analysis of the candidate tumor suppressor geneING1 in human head and neck tumors with 13q deletions., 2000, 27, 319-322.		37
261	Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Letters, 2001, 170, 73-79.	3.2	37
262	U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of & amp;Delta;Np63& amp;alpha;. Cell Cycle, 2008, 7, 1231-1237.	1.3	37
263	Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes. Cancer Biology and Therapy, 2018, 19, 773-785.	1.5	37
264	Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Research, 2003, 63, 7694-8.	0.4	37
265	Circulating DNA: What We Know and What We Need to Learn. Annals of the New York Academy of Sciences, 2000, 906, 1-4.	1.8	36
266	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle, 2013, 12, 1058-1070.	1.3	36
267	A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma. Scientific Reports, 2016, 6, 36132.	1.6	36
268	Early detection of gastric cancer using global, genome-wide and <i>IRF4, ELMO1, CLIP4</i> and <i>MSC</i> DNA methylation in endoscopic biopsies. Oncotarget, 2017, 8, 38501-38516.	0.8	36
269	p63-Specific Activation of the BPAG-1e Promoter. Journal of Investigative Dermatology, 2005, 125, 52-60.	0.3	35
270	A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochemical and Biophysical Research Communications, 2006, 339, 1120-1128.	1.0	35

#	Article	IF	Citations
271	RASSF1A hypermethylation and its inverse correlation withBRAF and/orKRAS mutations in MSI-associated endometrial carcinoma. International Journal of Cancer, 2006, 119, 1316-1321.	2.3	35
272	Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SVâ€HUCâ€1 cells. International Journal of Cancer, 2009, 125, 2829-2835.	2.3	35
273	An allelotype of papillary thyroid cancer. , 1996, 69, 442-444.		34
274	The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clinical Cancer Research, 2009, 15, 7658-7665.	3.2	34
275	Cigarette smoke and chewing tobacco alter expression of different sets of miRNAs in oral keratinocytes. Scientific Reports, 2018, 8, 7040.	1.6	34
276	Suprabasin Is Hypomethylated and Associated with Metastasis in Salivary Adenoid Cystic Carcinoma. PLoS ONE, 2012, 7, e48582.	1.1	34
277	Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression. PLoS ONE, 2013, 8, e70878.	1.1	34
278	Functional analysis of wild-type and malignant glioma derived CDKN2A $\hat{l}^2$ alleles: Evidence for an RB-independent growth suppressive pathway. Oncogene, 1997, 15, 2013-2020.	2.6	33
279	Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescencein situ hybridization., 1997, 74, 588-592.		33
280	Mitochondrial DNA alterations in thyroid cancer. Journal of Surgical Oncology, 2003, 82, 170-173.	0.8	33
281	PUMA in head and neck cancer. Cancer Letters, 2003, 199, 75-81.	3.2	33
282	Microsatellite analysis of serum DNA in patients with head and neck cancer. International Journal of Cancer, 2004, 111, 96-100.	2.3	33
283	Hypermethylation of Genes Detected in Urine from Ghanaian Adults with Bladder Pathology Associated with Schistosoma haematobium Infection. PLoS ONE, 2013, 8, e59089.	1.1	33
284	Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer. BMC Cancer, 2015, 15, 843.	1.1	33
285	Role of protein kinase N2 (PKN2) in cigarette smoke-mediated oncogenic transformation of oral cells. Journal of Cell Communication and Signaling, 2018, 12, 709-721.	1.8	33
286	Dose-Dependent Activation of Putative Oncogene SBSN by BORIS. PLoS ONE, 2012, 7, e40389.	1.1	33
287	ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer. Clinical Cancer Research, 2008, 14, 3754-3760.	3.2	32
288	An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. Scientific Reports, 2015, 5, 13236.	1.6	32

#	Article	IF	CITATIONS
289	Biomarkers for Lung Cancer Screening and Detection. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2411-2415.	1.1	32
290	Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochemical and Biophysical Research Communications, 2008, 365, 221-226.	1.0	31
291	Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1887-1893.	0.5	31
292	Identification of guanine nucleotide-binding protein $\hat{I}^3$ -7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling. International Journal of Oncology, 2013, 42, 1427-1436.	1.4	31
293	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	1.1	31
294	Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes. Cancer Biology and Therapy, 2015, 16, 1593-1603.	1.5	31
295	Promoter methylation of MCAM, $ER\hat{l}_{\pm}$ and $ER\hat{l}_{2}^{2}$ in serum of early stage prostate cancer patients. Oncotarget, 2017, 8, 15431-15440.	0.8	31
296	p63 Transcriptional Regulation of Epithelial Integrity and Cancer. Cell Cycle, 2007, 6, 240-245.	1.3	30
297	Silencing of highâ€mobility group box 2 (HMGB2) modulates cisplatin and 5â€fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics, 2015, 15, 383-393.	1.3	30
298	Following Mitochondrial Footprints through a Long Mucosal Path to Lung Cancer. PLoS ONE, 2009, 4, e6533.	1.1	30
299	Molecular markers in cancer: Can we make better predictions?. International Journal of Cancer, 1995, 64, 1-2.	2.3	29
300	Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes. Cancer Prevention Research, 2016, 9, 915-924.	0.7	29
301	Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. International Journal of Cancer, 2003, 107, 46-52.	2.3	28
302	Phospho-ΔNp63α/NF-Y protein complex transcriptionally regulates DDIT3 expression in squamous cell carcinoma cells upon cisplatin exposure. Cell Cycle, 2010, 9, 328-338.	1.3	28
303	SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. Journal of Molecular Medicine, 2013, 91, 381-393.	1.7	28
304	Cigarette smoke induces methylation of the tumor suppressor gene <i><i>NISCH</i>Epigenetics, 2013, 8, 383-388.</i>	1.3	28
305	Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics, 2014, 9, 308-317.	1.3	28
306	Real-Time Gap Ligase Chain Reaction. Clinical Cancer Research, 2004, 10, 2379-2385.	3.2	27

#	Article	IF	CITATIONS
307	Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncology, 2006, 42, 201-207.	0.8	27
308	Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer. Clinical Cancer Research, 2007, 13, 7199-7206.	3.2	27
309	Quantitative Methylation Profiles for Multiple Tumor Suppressor Gene Promoters in Salivary Gland Tumors. PLoS ONE, 2010, 5, e10828.	1.1	27
310	Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study. Clinical Cancer Research, 2013, 19, 2528-2540.	3.2	27
311	Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer. PLoS ONE, 2016, 11, e0144862.	1.1	27
312	In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. Cell Death Discovery, 2017, 3, 17022.	2.0	27
313	The Oral Cavity as a Molecular Mirror of Lung Carcinogenesis. Cancer Prevention Research, 2008, 1, 12-14.	0.7	26
314	Detection of Methylated CDO1 in Plasma of Colorectal Cancer; A PCR Study. PLoS ONE, 2014, 9, e113546.	1.1	26
315	Clusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 868-877.	3.2	26
316	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. Clinical Chemistry, 2020, 66, 105-116.	1.5	26
317	Fluorescence Visualization in Oral Neoplasia: Shedding Light on an Old Problem: Fig. 1 Clinical Cancer Research, 2006, 12, 6594-6597.	3.2	25
318	Dysregulation of splicing proteins in head and neck squamous cell carcinoma. Cancer Biology and Therapy, 2016, 17, 219-229.	1.5	25
319	Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer. OMICS A Journal of Integrative Biology, 2017, 21, 390-403.	1.0	24
320	MDA-9/Syntenin regulates differentiation and angiogenesis programs in head and neck squamous cell carcinoma. Oncoscience, 2014, 1, 725-737.	0.9	24
321	Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. International Journal of Cancer, 2012, 131, 158-164.	2.3	23
322	Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile. Future Oncology, 2015, 11, 233-249.	1.1	23
323	Germline Translocation t(5;20)(p15;q11) and Familial Transitional Cell Carcinoma. Journal of Urology, 1996, 155, 1035-1036. Molecular methods for the diagnosis of cancer1Oncor, Inc. provided research funding for the study	0.2	22
324	described in this paper. Under an agreement between Oncor and the Johns Hopkins University, Dr. Sidransky is entitled to a share of sales royalty received by the University from Oncor. Under that agreement, the University and Dr. Sidransky also have received Oncor stock which, under University policy, cannot be traded until two years after the first commercial sales of the products related to this research. The. Biochimica Et Biophysica Acta: Reviews on Cancer, 1999, 1423, C11-C18.	3.3	22

#	Article	IF	CITATIONS
325	Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer. Oncology Reports, 2014, 31, 1014-1020.	1.2	22
326	miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke. MicroRNA (Shariqah, United Arab Emirates), 2018, 7, 38-53.	0.6	22
327	Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome., 2000, 88, 433-439.		21
328	Regulation of î"Np63î± by NFîºî'Â. Cell Cycle, 2010, 9, 4841-4847.	1.3	21
329	<i>Paired Box 5</i> Methylation Detection by Droplet Digital PCR for Ultra-Sensitive Deep Surgical Margins Analysis of Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research, 2015, 8, 1017-1026.	0.7	21
330	MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Journal of Clinical Neuroscience, 2015, 22, 1938-1942.	0.8	21
331	Chronic Exposure to Chewing Tobacco Induces Metabolic Reprogramming and Cancer Stem Cell-Like Properties in Esophageal Epithelial Cells. Cells, 2019, 8, 949.	1.8	21
332	A Promoter Methylation Pattern in the <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 6658-6665.	3.2	20
333	Alterations of GPI transamidase subunits in head and neck squamous carcinoma. Molecular Cancer, 2007, 6, 74.	7.9	19
334	Tissue imprint for molecular mapping of deep surgical margins in patients with head and neck squamous cell carcinoma. Head and Neck, 2012, 34, 1529-1536.	0.9	19
335	<i>JAK3</i> Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prevention Research, 2019, 12, 255-270.	0.7	19
336	An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget, 2014, 5, 5218-5233.	0.8	19
337	Two Distinct Regions of Loss on Chromosome Arm 4q in Primary Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2000, 126, 1073.	1.5	18
338	Loss of chromosome arms 3p and 9p and inactivation of P16INK4a in normal epithelium of patients with primary lung cancer. Genes Chromosomes and Cancer, 2001, 32, 119-125.	1.5	18
339	Positive Correlation of Tissue Inhibitor of Metalloproteinase-3 and Death-Associated Protein Kinase Hypermethylation in Head and Neck Squamous Cell Carcinoma. Laryngoscope, 2007, 117, 1376-1380.	1.1	18
340	A <i>IM1</i> promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate, 2012, 72, 1133-1139.	1,2	18
341	Cigarette smoke induces mitochondrial metabolic reprogramming in lung cells. Mitochondrion, 2018, 40, 58-70.	1.6	18
342	Molecular Profiling Associated with Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2)-Mediated Carcinogenesis in Gastric Cancer. Journal of Proteome Research, 2021, 20, 2687-2703.	1.8	18

#	Article	IF	CITATIONS
343	Degenerate Oligonucleotide-Primed PCR (DOPPCR): Evaluation of its Reliability for Screening of Genetic Alterations in Neoplasia. BioTechniques, 1998, 25, 1036-1038.	0.8	17
344	The Potential of Molecular Screening. Surgical Oncology Clinics of North America, 1999, 8, 641-656.	0.6	17
345	Molecular Analysis of Peritoneal Fluid in Ovarian Cancer Patients. Modern Pathology, 2003, 16, 636-640.	2.9	17
346	Re: Is TIG1 a New Tumor Suppressor in Prostate Cancer?. Journal of the National Cancer Institute, 2003, 95, 919-920.	3.0	17
347	Yes-associated protein 1 regulates the stability of î"Np63î±. Cell Cycle, 2010, 9, 162-167.	1.3	17
348	Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma. Oral Oncology, 2011, 47, 251-255.	0.8	17
349	Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Epigenetics, 2020, 15, 959-971.	1.3	17
350	Epigenetic inactivation of <i>VGF</i> associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget, 2014, 5, 3350-3361.	0.8	17
351	Lack of BRCA2 alterations in primary head and neck squamous cell carcinoma. Otolaryngology - Head and Neck Surgery, 1998, 119, 21-25.	1.1	16
352	Use of single nucleotide polymorphism arrays to identify a novel region of loss on chromosome 6q in squamous cell carcinomas of the oral cavity. Head and Neck, 2004, 26, 345-352.	0.9	16
353	Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma. International Journal of Oncology, 2011, 39, 337-44.	1.4	16
354	Antiviral effect of ranpirnase against Ebola virus. Antiviral Research, 2016, 132, 210-218.	1.9	16
355	Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 677051.	1.3	16
356	Molecular detection of cervical intraepithelial neoplasia and cervical carcinoma by microsatellite analysis of Papanicolaou smears. International Journal of Cancer, 2001, 93, 424-429.	2.3	15
357	P63 and P73: Teammates or adversaries?. Cancer Cell, 2006, 9, 1-2.	7.7	15
358	Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Translational Research, 2018, 202, 109-119.	2.2	15
359	MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 18793.	1.6	15
360	Hyperactivation of MEK/ERK pathway by Ca <sup>2+</sup> /calmodulinâ€dependent protein kinase kinase 2Âpromotes cellular proliferation by activating cyclinâ€dependent kinasesÂand minichromosome maintenance proteinÂin gastric cancer cells. Molecular Carcinogenesis, 2021, 60, 769-783.	1.3	15

#	Article	IF	Citations
361	Cancer genetics: Two tracks but one race?. Current Biology, 1996, 6, 523-525.	1.8	14
362	Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. Journal of Cellular Biochemistry, 1997, 67, 64-73.	1.2	14
363	Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Medical Genetics, 2008, 9, 7.	2.1	14
364	Tumor Protein p63/Nuclear Factor κB Feedback Loop in Regulation of Cell Death. Journal of Biological Chemistry, 2011, 286, 43204-43213.	1.6	14
365	Ranpirnase Eradicates Human Papillomavirus in Cultured Cells and Heals Anogenital Warts in a Phase I Study. Antiviral Therapy, 2017, 22, 247-255.	0.6	14
366	Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. Oncoscience, 2018, 5, 21-38.	0.9	14
367	Whole-Exome Sequencing Analysis of Oral Squamous Cell Carcinoma Delineated by Tobacco Usage Habits. Frontiers in Oncology, 2021, 11, 660696.	1.3	14
368	Identification of mtDNA Mutations in Human Cancer. , 2002, 197, 107-117.		13
369	Absence of TSG101 transcript abnormalities in human cancers. Oncogene, 1998, 16, 2815-2818.	2.6	12
370	Genome-Wide and Gene-Specific Epigenomic Platforms for Hepatocellular Carcinoma Biomarker Development Trials. Gastroenterology Research and Practice, 2014, 2014, 1-9.	0.7	12
371	PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40ÂkDa (PRAS40). Journal of Cell Communication and Signaling, 2019, 13, 163-177.	1.8	12
372	Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters, 2020, 471, 49-60.	3.2	12
373	Comparative mutational landscape analysis of patient-derived tumour xenografts. British Journal of Cancer, 2017, 116, 515-523.	2.9	11
374	<i>HIST1H2BB</i> and <i>MAGI2</i> Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research, 2020, 13, 783-794.	0.7	11
375	Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma. Seminars in Radiation Oncology, 2004, 14, 130-138.	1.0	10
376	Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice. Oncotarget, 2017, 8, 88276-88293.	0.8	10
377	Clinical and public health research using methylated DNA Immunoprecipitation (MeDIP): A comparison of commercially available kits to examine differential DNA methylation across the genome. Epigenetics, 2012, 7, 106-112.	1.3	9
378	Prenatal exposure to tobacco smoke leads to increased mitochondrial DNA content in umbilical cord serum associated to reduced gestational age. International Journal of Environmental Health Research, 2017, 27, 52-67.	1.3	9

#	Article	IF	CITATIONS
379	Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma. Oral Oncology, 2017, 74, 192-193.	0.8	9
380	Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice. Aging, 2017, 9, 1660-1676.	1.4	9
381	Multiomic analysis of oral keratinocytes chronically exposed to shisha. Journal of Oral Pathology and Medicine, 2019, 48, 284-289.	1.4	9
382	Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 1797-1808.	1.9	9
383	Colorimetric approach to high-throughput mutation analysis. BioTechniques, 2005, 38, 635-639.	0.8	8
384	Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma. International Journal of Oncology, 2011, 38, 1129-35.	1.4	8
385	Understanding the MIG6–EGFR Signaling Axis in Lung Tumorigenesis. Cancer Discovery, 2015, 5, 472-474.	7.7	8
386	Growth of Triple Negative and Progesterone Positive Breast Cancer Causes Oxidative Stress and Down-Regulates Neuroprotective Transcription Factor NPAS4 and NPAS4-Regulated Genes in Hippocampal Tissues of TumorGraft Mice—an Aging Connection. Frontiers in Genetics, 2018, 9, 58.	1.1	8
387	Proteomic Changes in Oral Keratinocytes Chronically Exposed to Shisha (Water Pipe). OMICS A Journal of Integrative Biology, 2019, 23, 86-97.	1.0	8
388	Epigenetic silencing of S100A2 in bladder and head and neck cancers. Oncoscience, 2015, 2, 410-418.	0.9	8
389	High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing. Journal of Molecular Medicine, 2016, 94, 1015-1024.	1.7	7
390	Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Human Cell, 2017, 30, 226-236.	1.2	7
391	Identification of potential biomarkers of head and neck squamous cell carcinoma using iTRAQ based quantitative proteomic approach. Data in Brief, 2018, 19, 1124-1130.	0.5	7
392	Molecular alterations in oral cancer using high-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue. Journal of Cell Communication and Signaling, 2021, 15, 447-459.	1.8	7
393	Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics. Cancer Biomarkers, 2021, 31, 361-373.	0.8	6
394	Prognostic biomarkers in patients with human immunodeficiency virusâ€positive disease with head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 2433-2443.	0.9	5
395	Secretome analysis of oral keratinocytes chronically exposed to shisha. Cancer Biomarkers, 2019, 25, 29-41.	0.8	5
396	A robust and interpretable gene signature for predicting the lymph node status of primary <scp>T1</scp> / <scp>T2</scp> oral cavity squamous cell carcinoma. International Journal of Cancer, 2022, 150, 450-460.	2.3	5

#	Article	IF	CITATIONS
397	Uses of DNA Methylation in Cancer Diagnosis and Risk Assessment. , 2004, , 11-26.		5
398	Oncogene mutations as intermediate markers. Journal of Cellular Biochemistry, 1993, 53, 184-187.	1.2	4
399	TAp $63\hat{l}^3$ regulates hOGG1 and repair of oxidative damage in cancer cell lines. Biochemical and Biophysical Research Communications, 2007, 356, 823-828.	1.0	4
400	Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease. Respiratory Medicine, 2017, 124, 72-78.	1.3	4
401	Chronic shisha exposure alters phosphoproteome of oral keratinocytes. Journal of Cell Communication and Signaling, 2019, 13, 281-289.	1.8	4
402	Proteomic Alterations Associated with Oral Cancer Patients with Tobacco Using Habits. OMICS A Journal of Integrative Biology, 2021, 25, 255-268.	1.0	4
403	Role of the NOTCH Signaling Pathway in Head and Neck Cancer. Current Cancer Research, 2018, , 229-248.	0.2	4
404	Precision health diagnostic and surveillance network uses <i>S</i> gene target failure (SGTF) combined with sequencing technologies to track emerging SARSâ€CoVâ€2 variants. Immunity, Inflammation and Disease, 2022, 10, .	1.3	4
405	Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma. Frontiers in Genetics, 2022, 13, .	1.1	4
406	MICROSATELLITE DEOXYRIBONUCLEIC ACID ANALYSIS TO DETECT BLADDER CANCER IN BLADDER EXSTROPHY. Journal of Urology, 1998, 160, 2192-2193.	0.2	3
407	Comparative microsatellite analysis in discerning origin of disseminated tumor: The case of a patient with malignant ascites and a history of multiple tumors. Human Pathology, 1999, 30, 1111-1113.	1.1	3
408	INSIG2 rs7566605 single nucleotide variant and global DNA methylation index levels are associated with weight loss in a personalized weight reduction program. Molecular Medicine Reports, 2017, 17, 1699-1709.	1.1	3
409	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	2.3	3
410	Molecular analysis of effectiveness of Mohs' surgical technique. Lancet, The, 1996, 347, 1692-1693.	6.3	2
411	Growth of Malignant Non-CNS Tumors Alters Brain Metabolome. Frontiers in Genetics, 2018, 9, 41.	1.1	2
412	Signaling alterations in oral keratinocytes in response to shisha and crude tobacco extract. Journal of Oral Pathology and Medicine, 2021, 50, 459-469.	1.4	2
413	Proteomic and phosphoproteomic profiling of shammah induced signaling in oral keratinocytes. Scientific Reports, 2021, 11, 9397.	1.6	2
414	Detailed deletion mapping at chromosome 9p21 in nonâ€small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. International Journal of Cancer, 1997, 74, 588-592.	2.3	2

#	Article	IF	CITATIONS
415	Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1., 0, .		2
416	Absence of intragenic mismatch mutations in small cell lung cancers with microsatellite instability. , 1999, 80, 944-945.		1
417	Response to ?MMTV-related env sequences in human breast tumors?. International Journal of Cancer, 2003, 106, 139-139.	2.3	1
418	Testican 1 (SPOCK1) and protein tyrosine phosphatase, receptor type S (PTPRS) show significant increase in saliva of tobacco users with oral cancer. Translational Research in Oral Oncology, 2018, 3, 2057178X1880053.	2.3	1
419	First Person: David Sidransky, MD. Cancer, 2018, 124, 3077-3078.	2.0	1
420	Multi-Omics Analysis to Characterize Cigarette Smoke Induced Molecular Alterations in Esophageal Cells. Frontiers in Oncology, 2020, 10, 1666.	1.3	1
421	How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics. OMICS A Journal of Integrative Biology, 2021, 25, 605-616.	1.0	1
422	Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung., 2001, 92, 1525.		1
423	Investigation of curcumin-mediated signalling pathways in head and neck squamous cell carcinoma. Translational Research in Oral Oncology, 2017, 2, 2057178X1774314.	2.3	0
424	Molecular Detection of Head and Neck Cancer. , 2003, , 305-IV.		0
425	Reply to "Proteomic alterations of cancer-cell mitochondria: driver or bystander?― Nature Reviews Cancer, 2003, 3, 796-796.	12.8	0
426	Integrated genomics and avatar mouse models for personalized cancer treatment Journal of Clinical Oncology, 2013, 31, 2511-2511.	0.8	0
427	Abstract B25: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells. , 2014, , .		0